Home  ›  Md Anderson Drawing Blood Stem Cells

Md Anderson Drawing Blood Stem Cells

Written By Friday, 7 January 2022 Add Comment Edit

. 2009 Apr 30;113(18):4144-52.

doi: 10.1182/blood-2008-10-184200. Epub 2009 Jan 23.

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

Roland Bassett, Celina Ledesma, Martin Korbling, Amin Alousi, Chitra Hosing, Partow Kebraei, Robyn Harrell, Gabriela Rondon, Sergio A Giralt, Paolo Anderlini, Uday Popat, Barbara Pro, Barry Samuels, Frederick Hagemeister, L Jeffrey Medeiros, Richard E Champlin, Issa F Khouri

Affiliations

  • PMID: 19168784
  • PMCID: PMC4624445
  • DOI: 10.1182/blood-2008-10-184200

Free PMC article

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

Constantine S Tam  et al. Blood. .

Free PMC article

Abstract

In this study, we analyzed the long-term outcome of a risk-adapted transplantation strategy for mantle cell lymphoma in 121 patients enrolled in sequential transplantation protocols. Notable developments over the 17-year study period were the addition of rituximab to chemotherapy and preparative regimens and the advent of nonmyeloablative allogeneic stem cell transplantation (NST). In the autologous transplantation group (n = 86), rituximab resulted in a marked improvement in progression-free survival for patients who received a transplant in their first remission (where a plateau emerged at 3-8 years) but did not change the outcomes for patients who received a transplant beyond their first remission. In the NST group, composed entirely of patients who received a transplant beyond their first remission, durable remissions also emerged in progression-free survival at 5 to 9 years. The major determinants of disease control after NST were the use of a peripheral blood stem cell graft and donor chimerism of at least 95%, whereas the major determinant of death was immunosuppression for chronic graft-versus-host disease. Our results show that long-term disease-free survival in mantle cell lymphoma is possible after rituximab-containing autologous transplantation for patients in first remission and after NST for patients with relapsed or refractory disease.

Figures

Figure 1
Figure 1

Overall survival and progression-free survival. Overall survival (A) and progression-free survival (B). AUTO1 indicates patients receiving autologous transplant in first remission; AUTO2, patients receiving autologous transplant for relapsed/refractory disease; and NST, patients receiving nonmyeloablative stem cell transplant for relapsed/refractory disease.

Figure 2
Figure 2

Progression-free survival for patients receiving autologous transplantation in first remission and for relapsed/refractory disease. Patients received autologous transplant in first remission (A) and for relapsed/refractory disease (B).

Figure 3
Figure 3

Relapse risk after nonmyeloablative stem cell transplantation by graft source and best chimerism. PBSC indicates peripheral blood stem cell. No relapses have occurred in patients receiving PBSCs and achieving best donor chimerism of 95% or greater.

Similar articles

  • Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.

    Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL. Mangel J, et al. Semin Oncol. 2002 Feb;29(1 Suppl 2):56-69. Semin Oncol. 2002. PMID: 11842390 Review.

  • An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.

    Jacobsen E, Freedman A. Jacobsen E, et al. Curr Opin Oncol. 2004 Mar;16(2):106-13. doi: 10.1097/00001622-200403000-00004. Curr Opin Oncol. 2004. PMID: 15075900 Review.

  • Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.

    Zoellner AK, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, Topp M, Truemper L, Schmidt C, Bouabdallah K, Krauter J, Lenz G, Dürig J, Vergote V, Schäfer-Eckart K, André M, Kluin-Nelemans HC, van Hoof A, Klapper W, Hiddemann W, Dreyling M, Hoster E; European Mantle Cell Lymphoma Network. Zoellner AK, et al. Lancet Haematol. 2021 Sep;8(9):e648-e657. doi: 10.1016/S2352-3026(21)00195-2. Lancet Haematol. 2021. PMID: 34450102 Clinical Trial.

  • Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.

    Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M, Albitar M, Giralt S, Samuels B, Anderlini P, Rodriguez J, von Wolff B, Gajewski J, Cabanillas F, Champlin R. Khouri IF, et al. Ann Oncol. 1999 Nov;10(11):1293-9. doi: 10.1023/a:1008380527502. Ann Oncol. 1999. PMID: 10631455 Clinical Trial.

  • Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.

    Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Khouri IF, et al. J Clin Oncol. 2003 Dec 1;21(23):4407-12. doi: 10.1200/JCO.2003.05.501. J Clin Oncol. 2003. PMID: 14645431

Cited by 48 articles

  • Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.

    Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSG, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, Nishihori T, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Riedell PA, et al. Transplant Cell Ther. 2021 Nov;27(11):911.e1-911.e7. doi: 10.1016/j.jtct.2021.08.014. Epub 2021 Aug 24. Transplant Cell Ther. 2021. PMID: 34450333

  • Mantle Cell Lymphoma: Which Patients Should We Transplant?

    Gerson JN, Barta SK. Gerson JN, et al. Curr Hematol Malig Rep. 2019 Aug;14(4):239-246. doi: 10.1007/s11899-019-00520-0. Curr Hematol Malig Rep. 2019. PMID: 31218478 Review.

  • Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.

    Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL Jr, Vence LM, Allison JP, Gulbis AM, Sharma P. Khouri IF, et al. Clin Cancer Res. 2018 Mar 1;24(5):1011-1018. doi: 10.1158/1078-0432.CCR-17-2777. Epub 2017 Dec 15. Clin Cancer Res. 2018. PMID: 29246938 Free PMC article. Clinical Trial.

  • Double-Hit Large B Cell Lymphoma.

    Khelfa Y, Lebowicz Y, Jamil MO. Khelfa Y, et al. Curr Oncol Rep. 2017 Sep 26;19(11):74. doi: 10.1007/s11912-017-0629-y. Curr Oncol Rep. 2017. PMID: 28952038 Review.

  • Current approaches and advance in mantle cell lymphoma treatment.

    Liu Y, Zhang X, Zhong JF. Liu Y, et al. Stem Cell Investig. 2015 Sep 29;2:18. doi: 10.3978/j.issn.2306-9759.2015.09.02. eCollection 2015. Stem Cell Investig. 2015. PMID: 27358886 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

  • Full Text Sources

    • Elsevier Science
    • Europe PubMed Central
    • PubMed Central
    • Silverchair Information Systems

  • Medical

    • Genetic Alliance

Md Anderson Drawing Blood Stem Cells

Source: https://pubmed.ncbi.nlm.nih.gov/19168784/

0 Response to "Md Anderson Drawing Blood Stem Cells"

Post a Comment

Subscribe to: Post Comments (Atom)

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel